We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.57B
AUM Growth
+$29.7M
Cap. Flow
-$123M
Cap. Flow %
-7.84%
Top 10 Hldgs %
52.92%
Holding
277
New
83
Increased
54
Reduced
60
Closed
62

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.2M
2
MNKD icon
MannKind Corp
MNKD
+$15.2M
3
ABUS icon
Arbutus Biopharma
ABUS
+$4.32M
4
TWTR
Twitter, Inc.
TWTR
+$3.59M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.08M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.5M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$10.9M
3
GILD icon
Gilead Sciences
GILD
+$5.35M
4
AGEN
Agenus
AGEN
+$4.63M
5
NWBO
Northwest Biotherapeutics, Inc. Common stock
NWBO
+$3.79M

Sector Composition

Rank Sector Weight
1 Healthcare 9.13%
2 Communication Services 0.29%
3 Materials 0.04%
4 Financials 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PATH
76
PUT
DELISTED
NUPATHE INC COM STK
PATH
$2.29M 0.15%
7,014
+5,483
+358% +$12.2K
FOCL
77
EDAP TMS S.A.
FOCL
$227M
$2.29M 0.15%
770,618
-488,882
-39% -$1.36M
ARCT icon
78
Arcturus Therapeutics
ARCT
$163M
$2.28M 0.15%
+18,090
New +$2.27M
CASI
79
DELISTED
CASI Pharmaceuticals
CASI
$2.21M 0.14%
128,993
+11,097
+9% +$188K
INCY icon
80
CALL
Incyte
INCY
$26B
$2.18M 0.14%
431
– –
CPXX
81
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$2.18M 0.14%
+679,592
New +$2.33M
RIGL icon
82
Rigel Pharmaceuticals
RIGL
$712M
$2.17M 0.14%
76,290
+56,464
+285% +$1.66M
RMTI icon
83
PUT
Rockwell Medical
RMTI
$27.6M
$2.17M 0.14%
+18
New +$24.8K
BLUE
84
DELISTED
bluebird bio
BLUE
$2.14M 0.14%
+7,877
New +$2.2M
LLY icon
85
Eli Lilly
LLY
$1.09T
$2.08M 0.13%
40,700
+7,544
+23% +$378K
LLY icon
86
PUT
Eli Lilly
LLY
$1.09T
$2.08M 0.13%
407
– –
PBYI icon
87
CALL
Puma Biotechnology
PBYI
$406M
$1.99M 0.13%
+192
New +$11.3K
GEVA
88
CALL
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$1.84M 0.12%
285
-635
-69% -$37.7K
VNDA icon
89
Vanda Pharmaceuticals
VNDA
$310M
$1.82M 0.12%
+146,350
New +$1.47M
LXRX icon
90
Lexicon Pharmaceuticals
LXRX
$1.04B
$1.8M 0.11%
+142,857
New +$2.27M
SRNE
91
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$1.8M 0.11%
+222,026
New +$1.95M
CLDX icon
92
PUT
Celldex Therapeutics
CLDX
$2.79B
$1.67M 0.11%
46
-30
-39% -$11.6K
EXAS
93
PUT
DELISTED
Exact Sciences
EXAS
$1.63M 0.1%
+1,395
New +$16K
DCTH
94
DELISTED
Delcath Systems Inc
DCTH
$1.59M 0.1%
+24,401
New +$2.06M
ARIA
95
PUT
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$1.57M 0.1%
2,309
+680
+42% +$3.67K
ACHN
96
DELISTED
Achillion Pharmaceuticals
ACHN
$1.5M 0.1%
453,380
-31,499
-6% -$91.4K
VVUS
97
PUT
DELISTED
Vivus Inc
VVUS
$1.45M 0.09%
160
+99
+162% +$9.56K
ACAD icon
98
PUT
Acadia Pharmaceuticals
ACAD
$4.45B
$1.42M 0.09%
569
-264
-32% -$6.23K
TPST icon
99
Tempest Therapeutics
TPST
$13.9M
$1.39M 0.09%
52
-3
-5% -$82.3K
ARWR icon
100
CALL
Arrowhead Research
ARWR
$12.1B
$1.35M 0.09%
1,246
+807
+184% +$6.45K
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2013 Portfolio in Review

As of Q4 2013, Sabby Management held 277 positions worth $1.57B, up 1.9% from $1.54B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $123M in Q4 2013, closing 62 positions and reducing 60 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $23.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.1% of assets, down from 10% a quarter earlier, followed by Communication Services and Materials.

Against the trend, Sabby Management opened a new position in Arbutus Biopharma worth $4.14M.

  • Sabby Management's largest Q4 2013 buy was Arbutus Biopharma: 519,200 shares worth $4.14M.
  • Sabby Management added most to Teva Pharmaceuticals in Q4 2013, an estimated $17.2M increase.
  • Sabby Management's biggest Q4 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $10.9M.
  • Sabby Management fully exited Vertex Pharmaceuticals in Q4 2013, selling an estimated $23.5M.
  • Sabby Management's ten largest holdings make up 53% of its $1.57B portfolio in Q4 2013.
  • Sabby Management opened 83 new positions and closed 62 in Q4 2013.
  • Sabby Management's portfolio value rose 1.9% quarter-over-quarter to $1.57B.

Based on Sabby Management's 13F filing for Q4 2013, filed 14 Feb 2014.